血清FGF-23水平与慢性肾病患者进展为终末期肾病的关系

doi:10.3969/j.issn.1001-8131.2026.01.005

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (676 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective Exploring the relationship between serum FGF-23 levels and the progression of end-stage renal disease in patients with chronic kidney disease. Methods Select 97 end-stage renal disease(ESRD)patients undergoing hemodialysis at the Seventh Affiliated Hospital of Xinjiang Medical University between July,along with 30 healthy individuals receiving routine health examinations during the same period as the control group.Compare baseline characteristics,blood biochemical markers,and renal function parameters between the two groups.Evaluate clinical indicators and cardiorenal parameters across different CKD stages,and analyze the correlation between FGF-23 and renal function. Results The observation group exhibited significantly higher systolic blood pressure,diastolic blood pressure,mean arterial pressure,serum uric acid,and FGF-23 levels compared to the control group,while estimated glomerular filtration rate was lower(P<0.05).After treatment,the observation group showed significant reductions in BUN,SCr,FGF-2,FGF-23,Cyc-C,eGFR,left ventricular mass index,and ejection fractioncompared to pretreatment levels,whereas creatinine clearance rateincreased(P<0.05).Across the five CKD stages,eGFR progressively declined with disease progression,while parathyroid hormone(PTH)levels gradually increased.Significant intergroup differences were observed in uric acid,FGF-23,BUN,SCr,Ccr,FGF-2,Cyc-C,eGFR,PTH,LVMI,and LVEF(P<0.05).FGF-23 correlated negatively with BUN,SCr,Cyc-C,PTH,LVMI,and LVEF.BUN and SCr showed significant negative correlations with LVMI,LVEF,and eGFR but positive correlations with Cyc-C,FGF-2,and PTH.eGFR positively correlated with LVMI and LVEF but negatively with PTH.Cyc-C demonstrated a strong negative correlation with LVEF,while LVMI and LVEF were inversely related(all P<0.05). Conclusion FGF-23 can serve as an early and sensitive biomarker for the progression of chronic kidney disease to CKD,helping to identify high-risk patients at risk of early or rapid disease progression.High levels of FGF-23 are important factors in predicting the progression of end-stage renal disease(ESRD)in CKD patients.In the future,treatment strategies targeting FGF-23 can be developed and standardized testing can be promoted to break the vicious cycle of promoting CKD progression and cardiovascular damage.

Key words： Serum FGF-23 Chronic kidney disease End stage renal disease Disease progression Ccorrelation

Received: 03 February 2026

PACS:

R692

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Wang Yonglei
	Fan Jiajia
	He Yanyan

Cite this article:

Wang Yonglei,Fan Jiajia,He Yanyan. The Relationship between Serum FGF-23Levels, the Progression of Chronic Kidney Disease to End-stage Renal Disease in Patients[J]. journal1, 2026, 46(1): 15-19.

URL:

http://www.hrbyybjb.org.cn/EN/10.3969/j.issn.1001-8131.2026.01.005 OR http://www.hrbyybjb.org.cn/EN/Y2026/V46/I1/15

[1] 李阳,王一梅,李芳,等.“一带一路”国家慢性肾脏病的疾病负担及变化趋势研究[J].中华肾脏病杂志,2024,40(05):335-344.
[2] 郭晓凯,罗冬平,马向娟,等.三种血液净化模式对慢性肾衰竭患者血清FGF23、β2-MG、瘦素及骨代谢指标的影响[J].实验与检验医学,2023,41(03):254-257+266.
[3] 韩丽丽,张平,王芳,等.FGF23、orexin A、BMP-7在肾衰竭患者中的表达水平及与临床预后的关系[J].河北医科大学学报,2023,44(05):512-516+546.
[4] 秦启顺,王兴盛,徐世红,等.成纤维细胞生长因子23与慢性肾脏病相关骨质疏松[J].肾脏病与透析肾移植杂志,2024,33(6):561-566.
[5] 史新芬,周芸.成纤维细胞生长因子与缺氧诱导因子在慢性肾脏病血管钙化的研究进展[J].临床肾脏病杂志,2023,23(3):251-255.
[6] National Kidney Foundation.K/DOQI clinical practice guidelines for chronic kidney disease:evaluation,classification,and stratification[J].Am J Kidney Dis.2002,39(21):S1-266.
[7] Lima F,Monier-Faugere MC,Mawad H,David V,Malluche HH.FGF-23 and sclerostin in serum and bone of CKD patients[J].Clin Nephrol.2023,99(5):209-218.
[8] Deng Y,Zhang L,Chen S,et al.Exploring the clinical efficacy and mechanism of high-position colon dialysis combined with Traditional Chinese Medicine retention enema in real-world patients with stage 3-5 chronic kidney disease(non-dialysis)based on the theory of the Gut-Kidney axis[J].Front Pharmacol.2024,14:1246852.
[9] 陶晓阳,李花,郁胜强.β-CTX、UA、FGF-23与慢性肾衰竭透析患者矿物质-骨异常的关系[J].河北医科大学学报,2021,42(05):531-535.
[10] 陈惠霞,王玮玮,党珊,等.血清HO-1,HIF-1α及FGF23对腹膜透析患者血管钙化的影响[J].中国血液净化,2023,22(8):574-578.
[11] 何正佳,王娇,王成军,等.血清FGF23,Klotho蛋白与维持性血液透析患者心脏瓣膜钙化的相关性[J].中国临床医学,2024,31(2):215-220.
[12] 钱余锋,杨海明.血清FGF-23、可溶性α-Klotho蛋白与慢性肾脏病患者肾功能、钙磷代谢的相关性研究[J].中国中西医结合肾病杂志,2021,22(12):1112-1115.
[13] 吴振宇,田延锋,李芳,等.甲状旁腺全切联合前臂皮下自体移植对继发性甲状旁腺功能亢进症的疗效及对血清维生素D和FGF23的影响[J].中国现代普通外科进展,2024,27(8):648-651.
[14] 且代云,曹磊.Klotho蛋白、FGF23与糖尿病肾病肾损伤的相关研究[J].中国中西医结合肾病杂志,2025,26(01):42-44.
[15] 孟德欣,周晓萍,孟瑚,等.血清RANKL、OPG、FGF23与慢性肾脏病患者肾功能及钙磷代谢指标的相关性[J].昆明医科大学学报,2023,44(02):98-101.
[16] 王贵霞,李振翮,甄国栋,等.血清FGF-2,FGF-23与脓毒症合并急性肾损伤CRRT治疗患者肾功能及预后的关系[J].中国血液净化,2024,23(2):97-101.